Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is a complex group of malignancies that exhibit distinct clinical and molecular characteristics, especially in the HPV-negative subset. The treatment landscape for HPV-negative HNSCC has historically been limited to surgery, radiation, and chemotherapy,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024005168 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850176011552948224 |
|---|---|
| author | Madhan Krishnan Shyamaladevi Babu M.V. Vinaya Kumar Rajasekaran Subbarayan |
| author_facet | Madhan Krishnan Shyamaladevi Babu M.V. Vinaya Kumar Rajasekaran Subbarayan |
| author_sort | Madhan Krishnan |
| collection | DOAJ |
| description | Head and neck squamous cell carcinoma (HNSCC) is a complex group of malignancies that exhibit distinct clinical and molecular characteristics, especially in the HPV-negative subset. The treatment landscape for HPV-negative HNSCC has historically been limited to surgery, radiation, and chemotherapy, with these modalities often yielding suboptimal outcomes. The emergence of advanced immunotherapy represents a paradigm shift, offering new therapeutic options for this challenging cancer type. This review provides a comprehensive analysis of the latest advancements in immunotherapy for HPV-negative HNSCC, focusing on, chimeric antigen receptor (CAR) T-cell therapy, therapeutic cancer vaccines and immune checkpoint inhibitors. It also explores the potential benefits and limitations of combining immunotherapy with other treatment modalities including chemotherapy, targeted therapy, and radiation. Key challenges, including tumor heterogeneity, immunosuppressive microenvironment, and resistance mechanisms, are discussed. The review concludes with a look at future research directions and strategies to overcome these challenges and improve patient outcomes. |
| format | Article |
| id | doaj-art-567a3fb3f3324c9c8d2472a368fa2530 |
| institution | OA Journals |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-567a3fb3f3324c9c8d2472a368fa25302025-08-20T02:19:21ZengElsevierOral Oncology Reports2772-90602024-12-011210067010.1016/j.oor.2024.100670Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinomaMadhan Krishnan0Shyamaladevi Babu1M.V. Vinaya Kumar2Rajasekaran Subbarayan3Faculty of Research, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, 603103, Kelambakkam, Tamilnadu, India; Corresponding author.Faculty of Research, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, 603103, Kelambakkam, Tamilnadu, IndiaDepartment of Anatomy, Malla Reddy Medical College for Women, Suraram, 500055, Hyderabad, Telangana, IndiaCentre for Advanced Biotherapeutics and Regenerative Medicine, Faculty of Research, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, 603103, Kelambakkam, India; Centre for Herbal Pharmacology and Environmental Sustainability, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, 603103, IndiaHead and neck squamous cell carcinoma (HNSCC) is a complex group of malignancies that exhibit distinct clinical and molecular characteristics, especially in the HPV-negative subset. The treatment landscape for HPV-negative HNSCC has historically been limited to surgery, radiation, and chemotherapy, with these modalities often yielding suboptimal outcomes. The emergence of advanced immunotherapy represents a paradigm shift, offering new therapeutic options for this challenging cancer type. This review provides a comprehensive analysis of the latest advancements in immunotherapy for HPV-negative HNSCC, focusing on, chimeric antigen receptor (CAR) T-cell therapy, therapeutic cancer vaccines and immune checkpoint inhibitors. It also explores the potential benefits and limitations of combining immunotherapy with other treatment modalities including chemotherapy, targeted therapy, and radiation. Key challenges, including tumor heterogeneity, immunosuppressive microenvironment, and resistance mechanisms, are discussed. The review concludes with a look at future research directions and strategies to overcome these challenges and improve patient outcomes.http://www.sciencedirect.com/science/article/pii/S2772906024005168Advanced immunotherapyHPV-Negative HNSCCImmunotherapy innovationsTumor microenvironment |
| spellingShingle | Madhan Krishnan Shyamaladevi Babu M.V. Vinaya Kumar Rajasekaran Subbarayan Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinoma Oral Oncology Reports Advanced immunotherapy HPV-Negative HNSCC Immunotherapy innovations Tumor microenvironment |
| title | Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinoma |
| title_full | Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinoma |
| title_fullStr | Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinoma |
| title_full_unstemmed | Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinoma |
| title_short | Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinoma |
| title_sort | emergence of advanced immunotherapy new horizons for hpv negative head and neck squamous cell carcinoma |
| topic | Advanced immunotherapy HPV-Negative HNSCC Immunotherapy innovations Tumor microenvironment |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024005168 |
| work_keys_str_mv | AT madhankrishnan emergenceofadvancedimmunotherapynewhorizonsforhpvnegativeheadandnecksquamouscellcarcinoma AT shyamaladevibabu emergenceofadvancedimmunotherapynewhorizonsforhpvnegativeheadandnecksquamouscellcarcinoma AT mvvinayakumar emergenceofadvancedimmunotherapynewhorizonsforhpvnegativeheadandnecksquamouscellcarcinoma AT rajasekaransubbarayan emergenceofadvancedimmunotherapynewhorizonsforhpvnegativeheadandnecksquamouscellcarcinoma |